Nuclear transport proteins: Structure, function, and disease relevance
Y Yang, L Guo, L Chen, B Gong, D Jia… - Signal Transduction and …, 2023 - nature.com
Proper subcellular localization is crucial for the functioning of biomacromolecules, including
proteins and RNAs. Nuclear transport is a fundamental cellular process that regulates the …
proteins and RNAs. Nuclear transport is a fundamental cellular process that regulates the …
Adverse events reporting of XPO1 inhibitor-selinexor: a real-word analysis from FAERS database
Y Liu, R Yang, H Feng, Y Du, B Yang, M Zhang… - Scientific Reports, 2024 - nature.com
As the world's first oral nuclear export inhibitor, selinexor is increasingly being used in
clinical applications for malignant tumors. However, there is no extensive exploration on …
clinical applications for malignant tumors. However, there is no extensive exploration on …
[PDF][PDF] 塞利尼索治疗多药耐药的中枢神经系统复发的弥漫大B 细胞淋巴瘤1 例并文献复习
张鸿雁， 吴弘英， 于淑媛， 钟玉萍 - 临床血液学杂志, 2023 - lcxyen.whuhzzs.com
弥漫大B 细胞淋巴瘤是一种来源于成熟B 细胞的侵袭性肿瘤, 是最常见的非霍奇金淋巴瘤类型,
占全部非霍奇金淋巴瘤的25%~ 50%. 尽管一线治疗有效率50% 以上, 但仍有部分患者复发后 …
占全部非霍奇金淋巴瘤的25%~ 50%. 尽管一线治疗有效率50% 以上, 但仍有部分患者复发后 …
[PDF][PDF] Lymphomes diffus à grandes cellules B
A Bosly, M Delos, L Michaux - EMC, Hématologie, 2007 - dial.uclouvain.be
Les lymphomes diffus à grandes cellules B représentent près d'un tiers des lymphomes non
hodgkiniens, l'âge médian de leur survenue est de 70 ans et ils sont parfois liés aux déficits …
hodgkiniens, l'âge médian de leur survenue est de 70 ans et ils sont parfois liés aux déficits …
Selinexor treatment for diffuse large B-cell lymphoma with multidrug-resistant central nervous system recurrence: a case report and literature review
Z Hongyan, WU Hongying, YU Shuyuan… - J Clin …, 2023 - lcxyen.whuhzzs.com
Diffuse large B-cell lymphoma (DLBCL) is an aggressive tumor derived from mature B cells
and is the most common type of non-Hodgkin lymphoma, accounting for about 25%-50% of …
and is the most common type of non-Hodgkin lymphoma, accounting for about 25%-50% of …